The diagnostic and prognostic role of combined [^18F]FDG and [^68Ga]-DOTA-peptides PET/CT in primary pulmonary carcinoids: a multicentric experience

[1]  E. Pescarmona,et al.  Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  G. Patterson,et al.  Neuroendocrine Tumors of the Lung. , 2021, Thoracic surgery clinics.

[3]  R. Gatta,et al.  Role of 18F-FDG PET/CT Radiomics Features in the Differential Diagnosis of Solitary Pulmonary Nodules: Diagnostic Accuracy and Comparison between Two Different PET/CT Scanners , 2021, Journal of clinical medicine.

[4]  Gavin Wright,et al.  Pulmonary carcinoid tumours: A multi-centre analysis of survival and predictors of outcome following sublobar, lobar, and extended pulmonary resections , 2021, Asian cardiovascular & thoracic annals.

[5]  F. Molinari,et al.  Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms , 2021, Biomedicines.

[6]  C. Auernhammer,et al.  Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors , 2021, Diagnostics.

[7]  E. Baudin,et al.  Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Pelosi,et al.  Morphologic and molecular classification of lung neuroendocrine neoplasms , 2021, Virchows Archiv.

[9]  T. Derlin,et al.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT , 2020, The Journal of Nuclear Medicine.

[10]  T. Akhurst,et al.  Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  L. Evangelista,et al.  Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. , 2020, Clinical imaging.

[12]  A. Versari,et al.  Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features. , 2019, Interactive cardiovascular and thoracic surgery.

[13]  Z. Urakci,et al.  Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors , 2019, Nuclear medicine communications.

[14]  Guozhu Hou,et al.  The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid , 2019, Medicine.

[15]  Steven P Rowe,et al.  Novel Structured Reporting Systems for Theranostic Radiotracers , 2019, The Journal of Nuclear Medicine.

[16]  D. Groheux,et al.  FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review. , 2016, Diagnostic and interventional imaging.

[17]  R. Hicks,et al.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[18]  G. Rossi,et al.  Multicenter Comparison of 18F-FDG and 68Ga-DOTA-Peptide PET/CT for Pulmonary Carcinoid , 2015, Clinical nuclear medicine.

[19]  W. Travis,et al.  Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[21]  A. Cesario,et al.  PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids , 2014, Tumor Biology.

[22]  A. Nicolini,et al.  Neuroendocrine tumors of the lung: hystological classification, diagnosis, traditional and new therapeutic approaches. , 2014, Current medicinal chemistry.

[23]  L. Giovanella,et al.  Evolving role of PET/CT with different tracers in the evaluation of pulmonary neuroendocrine tumours , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  G. Pelosi,et al.  Grading the neuroendocrine tumors of the lung: an evidence-based proposal. , 2013, Endocrine-related cancer.

[25]  G. Treglia,et al.  Which is the best strategy for diagnosing bronchial carcinoid tumours? The role of dual tracer PET/CT scan. , 2014, Hellenic journal of nuclear medicine.

[26]  Rakesh Kumar,et al.  Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  T. Nakajima,et al.  Biological correlation of ¹⁸F-FDG uptake on PET in pulmonary neuroendocrine tumors. , 2013, Anticancer research.

[28]  Rakesh Kumar,et al.  Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids , 2011, Cancer imaging : the official publication of the International Cancer Imaging Society.

[29]  A. Groves,et al.  A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors , 2008, Journal of Nuclear Medicine.

[30]  Yu Kyeong Kim,et al.  Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. , 2008, Lung cancer.

[31]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .